AstraZeneca has cut about 600 jobs from its US respiratory and immunology commercial teams, Bloomberg News reported on November 13, 2026, citing people familiar with the matter. The reductions are among the first visible moves under the drugmaker's new three-year savings program, which aims to free up about $1.5 billion a year for reinvestment in its drug pipeline. AstraZeneca declined to comment on the report, according to Reuters.
AstraZeneca US job cuts, the key facts:
- Jobs affected: About 600 roles in US respiratory and immunology commercial teams, per Bloomberg News as reported by Reuters.
- Redeployment: Some affected employees are expected to be reassigned within the company.
- Savings program: "Reshaping for Sustainable Growth," targeting $1.5 billion in annualized pre-tax run-rate benefits.
- Cost and timing: Up to $2.0 billion in one-time restructuring costs, with activities essentially complete by the end of 2029.
- Company response: AstraZeneca declined to comment on the reported cuts.
- WARN filings: No 2026 AstraZeneca WARN notice has surfaced in public trackers as of November 16.
What Did AstraZeneca Cut, and Who Is Affected?
According to the Bloomberg report, summarized by Reuters, the roughly 600 positions sat in AstraZeneca's US respiratory and immunology commercial organization, the field and marketing teams that promote the company's asthma, COPD and immunology medicines to doctors. Not everyone in those roles is expected to leave: some employees are expected to move into other positions inside the company.
The reports did not identify specific US offices or states. Because sales representatives typically work in the field across many territories, the cuts may not concentrate at a single site.
Has AstraZeneca Filed a WARN Notice?
Federal and state WARN laws generally require employers to give 60 days' notice before mass layoffs or plant closings at a single site. As of November 16, 2026, the public database WARNTracker listed no AstraZeneca notices from 2025 or 2026; its most recent entry for the company is a January 2019 filing tied to closing sites in Boulder and Longmont, Colorado. Earlier AstraZeneca notices in the tracker were filed in Delaware in 2010, 2013 and 2016. A dispersed sales-force reduction may fall below single-site WARN thresholds, but GBNT could not confirm whether any state filing is pending.
What Is the $1.5 Billion Savings Plan?
AstraZeneca disclosed the program with its nine-month and third-quarter 2026 results on October 30. The company said it has "initiated the Reshaping for Sustainable Growth (RSG) programme to create additional capacity to invest behind its industry-leading pipeline and transformative technologies." It added that the program "is expected to cost up to $2.0bn in one-time restructuring costs and deliver $1.5bn in annualised pre-tax run-rate benefits," with savings "reinvested back into the Company, principally in the pipeline," and activities "essentially complete by the end of 2029."
At the time, the company did not expect the program to cause a net reduction in its workforce, Eastern Eye reported, with Chief Financial Officer Aradhana Sarin saying some positions would be eliminated while new roles would be created.
| Item | Figure | Source |
|---|---|---|
| Reported US job cuts | About 600 | Bloomberg via Reuters |
| Annual savings target | $1.5 billion pre-tax run-rate | AstraZeneca Q3 2026 results |
| One-time restructuring costs | Up to $2.0 billion | AstraZeneca Q3 2026 results |
| Completion | End of 2029 | AstraZeneca Q3 2026 results |
| Q3 2026 total revenue | $16.21 billion, up 7% at CER | AstraZeneca |
| Respiratory and immunology share of Q3 revenue | 16%, about $2.5 billion | Reuters |
How Is AstraZeneca's Business Performing?
The cuts come against solid headline growth. AstraZeneca reported third-quarter total revenue of $16.21 billion, up 7% at constant exchange rates, and reconfirmed its full-year 2026 guidance for a mid-to-high single-digit percentage rise in total revenue. Chief Executive Pascal Soriot said the company is "on track to deliver our 2030 ambition," a goal of $80 billion in annual revenue by 2030.
Respiratory and immunology accounted for 16% of third-quarter revenue, or about $2.5 billion, Reuters reported. For the first nine months, the therapy area generated $7.27 billion and grew 10% at constant exchange rates, according to the company.
How Do the Cuts Fit With AstraZeneca's US Investment Pledge?
The reductions contrast with AstraZeneca's growing US footprint. In July 2025 the company announced $50 billion of US investment by 2030, anchored by a drug substance plant planned for Virginia, plus expansions in Maryland, Massachusetts, California, Indiana and Texas. At the time it said it employed more than 18,000 people in the United States and expected half of its 2030 revenue to come from the US.
What Happens Next?
AstraZeneca has framed RSG as a reallocation rather than a downsizing, so further role changes across its commercial and support functions are possible as the program runs through 2029. Investors will look for an update on restructuring charges and headcount when the company reports full-year 2026 results, scheduled for February 9, 2027. Any state WARN filings tied to the US cuts would provide the first official count by location.
FAQs
How many US jobs did AstraZeneca cut?
About 600 jobs in its US respiratory and immunology commercial teams, according to Bloomberg News as reported by Reuters on November 13, 2026. Some affected staff are expected to be reassigned internally.
Did AstraZeneca confirm the layoffs?
No. AstraZeneca declined to comment on the report, Reuters said. The company has publicly confirmed only the broader savings program.
How much does AstraZeneca plan to save?
The Reshaping for Sustainable Growth program targets $1.5 billion in annualized pre-tax savings, costs up to $2.0 billion in one-time charges, and should be essentially complete by the end of 2029. Savings will mainly be reinvested in the drug pipeline.
Is AstraZeneca still investing in the US?
Yes. The company pledged $50 billion of US investment by 2030 in July 2025, including a new Virginia manufacturing plant.
Checked on November 16, 2026, against reporting by Reuters (citing Bloomberg News), Eastern Eye, AstraZeneca's 9M and Q3 2026 results and July 2025 investment release, and WARNTracker. This is a developing story and will be updated.